Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia i... ( Designed to improve on ex...)

Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.

Date:5/20/2008

Designed to improve on existing oral iron therapies

SAN ANTONIO, May 20 /PRNewswire/ -- Mission Pharmacal announced the launch of Ferralet(R) 90, a new prescription oral iron supplement for treatment of iron deficiency anemia (IDA) that is responsive to oral iron therapy. IDA is a depletion of stored iron that prevents maturation of red blood cells. Ferralet 90 contains 90 mg of carbonyl iron as well as essential vitamins and minerals to help patients replenish iron stores in an effective, safe and tolerable manner. Iron deficiency is the most common nutritional deficiency and the leading cause of anemia in the United States.(1)

"If left untreated, IDA has the potential to interfere with the body's vital functions, such as the nervous system, cardiovascular and immune system function. Women of child bearing age are at highest risk of developing iron deficiency anemia, and screening for IDA should be part of every woman's annual medical check up exam," said Miriam Nelson, Ph.D., a leading health and nutrition expert and author of the best-selling Strong Women book series. "The good news is that new IDA supplements, such as Ferralet 90, that are effective and tolerable can help restore iron levels back into normal range."

One in five women is iron deficient and at risk for developing anemia.(2) Menstruation is a leading cause of iron deficiency anemia in women by the Centers for Disease Control and Prevention.(3)

Women with IDA may better tolerate Ferralet 90 over other traditional iron supplements. Ferralet 90 contains carbonyl iron, which works with the body to regulate absorption at a rate determined by gastric acid production. This prolonged solubilization and absorption is the key to carbonyl iron's safety and tolerability.(4) Ferralet 90 is free of lactose and gluten, features a vanilla scent and contains docusate sodium, a gentle and effective stool softener, to help prevent side effects that may occur in women who are
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
2. Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility
3. Providing Affordable Health Care Coverage Cited as a Top Priority, Commissioner Says
4. Mission Community Hospital Hosts Spring Fundraiser to Refurbish Treasured Valley Emergency Room
5. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
6. The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA)
7. EPA Recognizes Fort Wayne Community Schools for Reducing Diesel Emissions From Its School Buses
8. Mesa Labs to Participate in the Health-Care Trade Policy Mission in Beijing on April 23-25, 2008
9. Gleevec Pushes Advanced Melanoma Into Remission
10. Joint Commission Alert: Prevent Pediatric Medication Errors
11. Admission-Day Crowding May Increase Hospital Stay for Children With Less Complicated Illnesses

Post Your Comments:

Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia i...( Designed to improve on ex...),Health